Biopharmaceutical company Revance Therapeutics has raised $104 million in Series E financing, including $33 million in cash and a conversion of $71 million in convertible debt into Series E preferred stock. Investors include Essex Woodlands Health Ventures, NovaQuest Capital Management, Delphi Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Bio*One Capital, Pac-Link Management Corp. and Palo Alto Investors. Revance is a developer of aesthetic and therapeutic dermatology products. The company will use the proceeds to support Phase 3 trials for the topical delivery of botulinum toxin type A, a therapy for crow’s feet wrinkles.
Developer of aesthetic and therapeutic dermatology products